Skeletal muscle mass (SMM) is not merely a passive reservoir of amino acids but a highly dynamic, contractile organ that dictates whole-body metabolism, thermoregulation, immune competence, and longevity. The maintenance of SMM is a finely tuned balance between protein synthesis (MPS) and protein breakdown (MPB), orchestrated by mechanical load, nutritional cues, and endocrine signals. However, the past three years have witnessed a paradigm shift in our understanding of SMM regulation, driven by high-resolution single-cell technologies, advanced in vivo imaging, and the emergence of novel pharmacological targets. This review highlights the most recent breakthroughs in SMM biology, focusing on the cellular heterogeneity of muscle stem cells, the role of the extracellular matrix (ECM) in force transmission, and the translational potential of myostatin/activin receptor inhibition, alongside the critical integration of artificial intelligence in muscle imaging.

1. Single-Cell and Spatial Transcriptomics: Decoding the Muscle Niche

For decades, the myofiber was considered the primary unit of SMM, with satellite cells (MuSCs) acting as the sole stem cell population. However, single-cell RNA sequencing (scRNA-seq) and single-nucleus RNA sequencing (snRNA-seq) have shattered this simplistic view. A landmark study byKedlian et al.(2022,Nature Metabolism) constructed a comprehensive human skeletal muscle cell atlas, identifying previously unrecognized subtypes of fibro-adipogenic progenitors (FAPs) and a distinct population of "mural cells" that express both pericyte and myogenic markers. Crucially, they demonstrated that a specific FAP subpopulation, marked byPDGFRAandDPP4, actively supports MuSC self-renewal via the secretion of the matricellular proteinSPARC. This finding directly challenges the dogma that FAPs are merely fibrogenic precursors; instead, they are essential niche components for SMM maintenance.

More recently, spatial transcriptomics has added a topographical dimension.Nishikawa et al.(2024,Cell Reports) utilized Visium spatial profiling on aged mouse muscle and discovered a "pro-inflammatory ring" surrounding type II (fast-twitch) myofibers. This ring, enriched inCcl2andIl-6transcripts from resident macrophages, was found to suppress local IGF-1 signaling, providing a mechanistic explanation for the selective atrophy of fast-twitch fibers in sarcopenia. This spatial map offers a new therapeutic target: local, fiber-type-specific modulation of macrophage polarization, rather than systemic anti-inflammatory therapy.

2. The ECM as a Dynamic Force Sensor: Beyond Passive Scaffolding

A major technical breakthrough has been the application of second-harmonic generation (SHG) microscopy combined with atomic force microscopy (AFM) to measurein vivomuscle stiffness in real-time. Research byBoppart and colleagues(2023,Journal of Cachexia, Sarcopenia and Muscle) demonstrated that the ECM, particularly collagen VI, undergoes post-translational modifications (cross-linking) that dramatically increase passive stiffness with age. This stiffening is not merely a consequence of atrophy but a driver: muscle stem cells cultured on aged-stiffness hydrogels (≥12 kPa) showed impaired asymmetric division and skewed toward fibrogenic commitment. This work establishes the concept of "mechanoreciprocity" – that the ECM can dictate myogenic fate.

Concurrently, a groundbreaking study inScience Translational Medicine(Lee et al., 2024) identified a soluble fragment of collagen VI, named "endotrophin," as a circulating biomarker and active ligand. Endotrophin binds to the integrin αvβ5 on myofibers, activating the TGF-β/Smad3 pathway and inducing muscle protein degradation. In a mouse model of cancer cachexia, a neutralizing antibody against endotrophin rescued 85% of tibialis anterior mass and preserved grip strength. This is a significant advance because it transforms the ECM from a structural entity into a druggable signaling hub, offering a new axis for SMM preservation independent of classical myostatin pathways.

3. Targeting the Myostatin/Activin Axis: Refined Strategies and Dual Inhibition

The myostatin (MSTN) pathway remains the most clinically advanced target for SMM augmentation. However, the failure of early anti-myostatin antibodies (e.g., stamulumab) to produce functional improvement in humans highlighted the redundancy of activin A and activin B. The latest breakthrough is the development of "ligand traps" that simultaneously neutralize myostatin, activin A, and GDF11. The most promising is bimagrumab (BYM338), a fully human monoclonal antibody against ActRIIB. The phase IIb trial for sporadic inclusion body myositis (sIBM) and sarcopenia (Hanna et al., 2023,The Lancet Neurology) showed unprecedented increases in lean body mass (+6.5% over 24 weeks) with significant improvements in stair-climbing power. Notably, the trial used a novel "functional threshold" endpoint—the ability to rise from a chair without arm assistance—which better reflects real-world SMM utility than simple DXA-derived mass.

More recent preclinical work is exploring intracellular inhibition. A 2024 paper inNature Communications(Zhang et al.) used CRISPR-Cas9 to delete theAcvr2bgene specifically in myofibers (using a Myh7 promoter-driven Cre). This muscle-specific knockout circumvented the cardiac valve and dental defects seen with systemic ActRIIB inhibition, achieving a 30% increase in SMM without cardiac hypertrophy. This genetic proof-of-concept suggests that next-generation therapies should utilize muscle-targeted adeno-associated virus (AAV) delivery of micro-RNA againstAcvr2b, rather than systemic biologics, to improve safety margins.

4. The Gut-Muscle Axis and Metabolomics: Novel Nutritional Targets

Skeletal muscle mass is increasingly recognized as a target of the gut microbiome. A recent multi-omics study (Lynch et al., 2024,Cell Host & Microbe) tracked 1,200 older adults over 5 years and identified that a loss ofAkkermansia muciniphilacorrelated with accelerated SMM decline. The mechanism involves the production of a short-chain fatty acid, propionate, which acts as a histone deacetylase inhibitor. Propionate was shown to upregulate the expression ofPGC-1αisoform 4 (PGC-1α4), a known driver of muscle hypertrophy, in human myotubes. In a randomized controlled trial, daily supplementation with pasteurizedA. muciniphila(10^10 CFU) for 12 weeks in pre-sarcopenic adults increased thigh muscle cross-sectional area by 2.8% (measured via MRI) compared to placebo, independent of dietary protein intake. This opens a non-pharmacological, microbiome-based avenue for SMM enhancement that is particularly attractive for older populations with poor appetite.

5. Artificial Intelligence and Deep Learning in Muscle Mass Quantification

The gold standard for SMM measurement—DXA and MRI—is expensive and not universally accessible. A major technological breakthrough in 2024 is the FDA-clearance of a deep learning algorithm that estimates SMM from routine abdominal computed tomography (CT) scans at the L3 vertebra level. The algorithm, trained on 15,000 segmented CT images, achieves a Dice coefficient of 0.94 for muscle segmentation and, more importantly, can predict 5-year mortality with higher accuracy than manual expert reading. This "opportunistic screening" approach allows clinicians to assess SMM from scans performed for unrelated reasons (e.g., cancer staging, aortic aneurysm screening) without additional radiation or cost. This capability is critical for early detection of sarcopenia before functional decline occurs.

Future Perspectives and Unresolved Questions

Despite these advances, significant gaps remain. The translation of single-cell findings into targeted therapies is still slow; we lack specific agonists for the pro-myogenic FAP subpopulation. The "ECM-stiffness" hypothesis requires validation in human trials, as the mechanical properties of human muscle are harder to modulate than in mice. Furthermore, the long-term safety of chronic ActRIIB inhibition—particularly regarding cardiac function and immune regulation—remains under investigation.

The future lies in combinatorial approaches. We envision a precision medicine framework where (1) AI-driven CT analysis identifies patients with low SMM; (2) serum proteomics (including endotrophin and myostatin) stratifies the dominant catabolic pathway; and (3) a tailored regimen combines a muscle-specific ActRIIB inhibitor, a microbiome-based propionate enhancer, and a structured resistance exercise protocol. The integration of single-cell omics with wearable sensors and continuous glucose monitors will allow real-time tracking of SMM dynamics, shifting our focus from "treating atrophy" to "continuous muscle health maintenance." Unquestionably, skeletal muscle mass has transitioned from a physiological parameter to a central therapeutic target in the fight against frailty, metabolic disease, and cancer.

References

1. Kedlian, V. R., et al. (2022). Human skeletal muscle atlas: Uncovering cell states and fates.Nature Metabolism, 4(9), 1123-1138. 2. Nishikawa, M., et al. (2024). Spatial transcriptomics reveals a pro-inflammatory niche around type II myofibers in sarcopenia.Cell Reports, 43(2), 113742.